A Phase 4 interventional study of Peginesatide and Epoetin alfa in Anemia, sponsored by Amgen. Terminated at 23 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-21.
Sponsored by Amgen · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing peginesatide in Anemia — none open to participants now, none under way, none of them phase 3. peginesatide · Anemia.
Among the 20 studies testing peginesatide in Anemia, this one is the 16th largest by enrollment, is the only one that started in 2012, is the only one in phase 4, and was the 19th registered.
1,810 studies on the registry are indexed under Anemia; 214 are open to participants now.
Browse Anemia studies →None of the 20 studies testing peginesatide in Anemia is open now. The open studies under Anemia, anywhere →
peginesatide: first FDA approval 2012 (OMONTYS). What it is approved for, and how studies give it, is on its page →
Of the 121 Anemia studies recruiting now, 67 (55%) set no upper age limit and 36 (30%) stop at 75 or younger; 33 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 97 across the 20 interventional studies. Of the 20 that completed or were terminated, 13 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 4 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
62 studies in Anemia by Amgen: none open now, none under way, none of them phase 3. Of 61 finished, 15 (25%) have results posted.
Among the 62 studies in Anemia by Amgen, this one is the 42nd largest by enrollment of the 44 interventional ones that give a count, is one of 3 that started in 2012, is one of 11 in phase 4, and was the 57th registered.
Amgen’s Anemia studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing peginesatide in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 62 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate whether hemodialysis patients on peginesatide can be converted to epoetin alfa by using a predefined conversion table while achieving a stable hemoglobin.
This is a phase 4, multicenter, single-arm, open-label study designed to evaluate whether patients receiving hemodialysis and treated with peginesatide can be converted to epoetin alfa using a predefined conversion table while achieving stable hemoglobin. The study will be conducted in two phases. Hemodialysis patients treated with epoetin alfa 3 times a week (TIW) will first be converted to peginesatide administered every 4 weeks (Q4W). After 24 weeks, these participants will be converted back to epoetin alfa administered TIW for 32 weeks. The primary endpoint will be the mean hemoglobin during the last 8 weeks of the epoetin alfa period.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were treated with peginesatide administered intravenously (IV) every 4 weeks for 24 weeks. Participants were then to be converted back to epoetin alfa administered by IV 3 times a week for 32 weeks.
Drug: Peginesatide · Drug: Epoetin alfa
All participants will receive peginesatide for the first 24 weeks.
Also known as: Omontys
All participants converted to epoetin alfa at week 25 for a total of 32 weeks
Also known as: Epogen
Mean Hemoglobin Concentration During the Evaluation Period
The hemoglobin concentrations during the evaluation period after the conversion to epoetin alfa were to be averaged for each participant and then summarized over all participants. No participant reached the evaluation period, therefore, the primary efficacy endpoint could not be evaluated.
Time frame: Last 8 weeks of epoetin alfa treatment period period (Weeks 49 to 56).
Mean Dose of Epoetin Alfa During the Evaluation Period
No participant reached the evaluation period, therefore, this endpoint could not be evaluated.
Time frame: Last 8 weeks of epoetin alfa treatment period period (Weeks 49 to 56).
Hemoglobin Concentration by Visit
Time frame: Baseline and Weeks 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21
Peginesatide Dose by Visit
Time frame: Baseline and Weeks 5, 9, 13, and 17
First patient was enrolled on 24 October 2012; Last patient was enrolled on 21 February 2013. The study was terminated on 27 March 2013.
| Milestone | Peginesatide |
|---|---|
| Started | 41 |
| Received peginesatide | 34 |
| Transitioned to epoetin alfa | 0 |
| Completed | 0 |
| Not completed | 41 |
| Withdrew: Death | 1 |
| Withdrew: Sponsor decision | 40 |
The hemoglobin concentrations during the evaluation period after the conversion to epoetin alfa were to be averaged for each participant and then summarized over all participants. No participant reached the evaluation period, therefore, the primary efficacy endpoint could not be evaluated.
No measurements were reported for this outcome.
No participant reached the evaluation period, therefore, this endpoint could not be evaluated.
No measurements were reported for this outcome.
| g/dL | Peginesatide |
|---|---|
| Baseline (n=34) | 10.51 ± 0.76 |
| Week 3 (n=34) | 11.09 ± 0.81 |
| Week 5 (n=29) | 10.86 ± 0.87 |
| Week 7 (n=21) | 11.03 ± 1.02 |
| Week 9 (n=20) | 10.59 ± 0.84 |
| Week 11 (n=19) | 10.80 ± 0.97 |
| Week 13 (n=14) | 10.50 ± 0.94 |
| Week 15 (n=10) | 10.70 ± 0.82 |
| Week 17 (n=10) | 10.35 ± 1.31 |
| Week 19 (n=10) | 10.93 ± 0.94 |
| Week 21 (n=1) | 10.10 ± NA |
| End of study visit (n=32) | 10.55 ± 0.63 |
| mg | Peginesatide |
|---|---|
| Baseline (n=30) | 5.42 ± 2.48 |
| Week 5 (n=16) | 5.04 ± 1.32 |
| Week 9 (n=15) | 4.98 ± 2.00 |
| Week 13 (n=9) | 4.00 ± 2.53 |
| Week 17 (n=9) | 5.12 ± 3.29 |
Collected over From informed consent up to 30 days post treatment, or end of study. Maximum time on study was 6 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Peginesatide | — | 3/34 (8.8%) | 6/34 (17.6%) |
| Event | Peginesatide |
|---|---|
| Ventricular asystoleCardiac disorders | 1/34 |
| Small intestinal obstructionGastrointestinal disorders | 1/34 |
| CholelithiasisHepatobiliary disorders | 1/34 |
| GastroenteritisInfections and infestations | 1/34 |
| PneumoniaInfections and infestations | 1/34 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/34 |
| Pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 1/34 |
| Event | Peginesatide |
|---|---|
| OedemaGeneral disorders | 2/34 |
| HeadacheNervous system disorders | 2/34 |
| HypertensionVascular disorders | 2/34 |
| Age, Continuous(years) | Peginesatide |
|---|---|
| Mean | 63.2 ± 16.6 |
| Sex: Female, Male(Participants) | Peginesatide |
|---|---|
| Female | 21 |
| Male | 20 |
| Race/Ethnicity, Customized(participants) | Peginesatide |
|---|---|
| Black or African American | 24 |
| White | 16 |
| Other | 1 |
The record gives a start of Oct 2012, a primary completion of Mar 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Peginesatide · Epoetin Alfa